Suppr超能文献

结直肠癌的预后和预测因素

Prognostic and predictive factors in colorectal cancer.

作者信息

Zlobec I, Lugli A

机构信息

Institute of Pathology, University Hospital of Basel, Basel, Switzerland.

出版信息

J Clin Pathol. 2008 May;61(5):561-9. doi: 10.1136/jcp.2007.054858. Epub 2008 Mar 6.

Abstract

Prognostication of newly diagnosed colorectal cancer (CRC) predominantly relies on stage as defined by the UICC-TNM and American Joint Committee on Cancer classifications. Tumour extent, lymph node status, tumour grade and the assessment of lymphatic and venous invasion are still the most important morphological prognostic factors. Evidence suggests that tumour budding and tumour border configuration are important, additional histological parameters but are not regarded as essential in prognosis. Although several molecular features, such as LOH18q and TP53 mutation analysis, have shown promising results in terms of their prognostic value, the American Society of Clinical Oncology Tumor Markers Expert Panel does not currently recommend their use in routine practice. cDNA-microarray, PCR and fluorescence in situ hybridisation are now frequently used to identity potential prognostic indicators in CRC, but the applicability of these methods in routine use is likely to have limited impact. Reliable prognostic markers identified by immunohistochemical protein profiling have yet to be established. Randomisation of data sets, assessment of interobserver variability for protein markers and scoring systems, as well as the use of receiver operating characteristic curve analysis in combination with multimarker-phenotype analysis of several different markers may be an effective tactical approach to increase the value of immunohistochemical findings. This article reviews the well established and additional prognostic factors in CRC and explores the contribution of molecular studies to the prognostication of patients with this disease. Additionally, an approach to improve the prognostic value of immunohistochemical protein markers is proposed.

摘要

新诊断结直肠癌(CRC)的预后主要取决于国际抗癌联盟(UICC)-TNM和美国癌症联合委员会分类所定义的分期。肿瘤范围、淋巴结状态、肿瘤分级以及淋巴管和静脉侵犯的评估仍然是最重要的形态学预后因素。有证据表明,肿瘤芽生和肿瘤边界形态是重要的额外组织学参数,但在预后评估中并不被视为必需因素。尽管一些分子特征,如18号染色体长臂杂合性缺失(LOH18q)和TP53突变分析,在预后价值方面已显示出有前景的结果,但美国临床肿瘤学会肿瘤标志物专家小组目前不建议在常规实践中使用这些指标。cDNA微阵列、聚合酶链反应(PCR)和荧光原位杂交现在经常用于识别CRC中的潜在预后指标,但这些方法在常规应用中的适用性可能影响有限。通过免疫组化蛋白质谱分析确定的可靠预后标志物尚未确立。对数据集进行随机分组、评估蛋白质标志物和评分系统的观察者间变异性,以及结合几种不同标志物的多标志物表型分析使用受试者工作特征曲线分析,可能是提高免疫组化结果价值的有效策略。本文综述了CRC中已确立的和额外的预后因素,并探讨了分子研究对该疾病患者预后评估的贡献。此外,还提出了一种提高免疫组化蛋白质标志物预后价值的方法。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验